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Abstract
Since the antiretroviral therapy (ART) was introduced to patients infected by human immunodeficiency virus (HIV), the HIV
related mortality and morbidity have been significantly reduced. The major obstacle for long-term successful anti-HIV
treatment is the emergence of drug resistant mutants. Current data of drug resistance was mainly obtained on HIV-1
subtype B but rarely on non-B virus, even more rare with newly emerged circulating recombinant forms (CRFs). The lack of
such data limits the rational management of ART for the increasing number of patients infected by non-subtype B virus. In
this study, a HIV-1 CRF07_BC strain CNGZD was isolated from a HIV patient and its genome was sequenced and deposited in
GenBank (JQ423923). Potential drug resistant mutants of this CRF07_BC virus strain were selected in PBMCs cultures in the
presence of Nevirapine (NVP), which is the most frequently used antiretroviral drug in China. Four combination profiles of
mutations were identified in the NVP-selected mutants, which were initiated with A98G, V108I, Y181C and I135T/I382L and
followed by more than two other mutations at the end of the selections, respectively. A total of seven previously reported
mutations (A98G, V106M, V108I, I135T, Y181C, V189I, K238N) and seven novel mutations (P4H, T48I, I178M, V314A, I382L/V,
T386A) in the reverse transcriptase gene were found in these NVP-selected mutants. Phenotypic analysis in the NVP-selected
mutants showed that all the mutations, except P4H, contribute to NVP resistance. Among them, V106M and Y181C reduce
NVP susceptibility for more than 20-fold, while the other mutations cause less than 20 folds drug resistance. Although the
information obtained in this in vitro selection study may not fully cover resistant mutations which will actually occur in
patients, it has still provided useful information for rational management of ART in patients infected with HIV CRF_BC
subtype.
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Introduction
Circulating recombinant forms (CRFs) are the virus with
recombinant genomes from different subtypes, which have been
detected as epidemic strains and displayed as their identifying
numbers and with letters presenting the involved subtypes [1].
Studies of HIV-1 subtypes and recombinants distributions in
worldwide have showed that the proportion of CRFs increased
from 12% in 2000–2003 to 16% in 2004–2007 and CRFs may
account for more and more infection cases in the coming years [2].
In China, CRF07_BC was originally found in Yunnan province
and spread out through one of the heroin trafficking route from
Yunnan to the northwestern provinces Sichuan, Gansu, Ningxia
and Xinjiang, and then across the border to Kasakhstan [3,4]. It
has been reported that CRF07_BC became the most prevalent
subtype in China (50.20%) in 2004 [5] and the most dominant
subtype in the newly diagnosed patients in Beijing (32.5%) in
2006–2007 [6].
Nevirapine (NVP), the first generation of nonnucleoside reverse
transcriptase (RT) inhibitor (NNRTI), is widely used with
nucleoside RT inhibitor (NRTI) as the first line antiretroviral
regimens, while NVP-containing highly active antiretroviral
therapy (HAART) is the most popular drug combination in China
[7]. Similar to the other NNRTIs, NVP binds to RT through a
hydrophobic pocket adjacent the active site of the enzyme. NVP
shows low genetic barrier for resistant mutations and resistant
mutation profiles of NVP always overlap with those of other
NNRTIs [8]. Furthermore, genetic diversity in different subtypes
or CRFs may affect the drug resistance development in patients
[9]. Thus far, the limited information for potential drug resistance
of CRF07_BC was based on the investigation in treatment naı¨ve
patients but not from treatment failure patients [5]. The genotypes
and phenotypes of the potential drug-resistant mutations in
treatment naı¨ve patients still remain unclear after receiving
HAART. With the increasing cases of CRF07_BC infection,
more and more patients will be given antiviral therapy. To
improve managements of NVP-containing antiretroviral therapy
for these patients, it is urgent to know the NVP resistant mutation
profiles in CRF07_BC. However, in the current studies based on
treatment failure patients, drug-resistance cannot be diagnosed
before the treatment failure, which always needs several years.
In the present study, we cultured clinical isolated CRF07_BC
virus with increasing concentration of NVP in PBMC to induce
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NVP associated mutations in vitro and further analyzed phenotypes
of these mutations by comparing levels of NVP resistance among
the induced CRF07_BC mutants. The study results will provide
important information of NVP resistant mutations for improving
the management of NVP containing antiviral treatment for
patients carrying CRF07_BC virus.
Materials and Methods
Virus Strain and Compound
The virus strain of CRF07_BC was isolated from a 32-year-old
female injection drug user (IDU) living in Guangzhou. Patient’s
blood sample was collected by Guangzhou CDC in 2007 when the
patient was asymptomatic and did not start antiviral treatment.
Virus was isolated by co-culture of patient’s PBMC with healthy
PBMC in RPMI 1640 supplemented with 10% fetal bovine serum
and antibiotics and 1 mg/ml interleukin-2 (IL-2) and was named as
CNGZD. Biological clones of CNGZD were also prepared using a
limiting dilution protocol [10]. The isolated virus was quantified
by blue focus units (BFU) assay as described previously [11,12].
Briefly, virus stock was 3 to 10-fold serially diluted by DMEM
complete culture medium containing 25 mg/ml DEAE and
inoculated to TZM-bl cells seeded in a 96 well plate. The infected
cells were incubated at 37uC for 48 hrs and stained with X-Gal
solution. After two hours incubation at 37uC, the blue cells were
easily visualized and counted under light microscopy. NVP was
provided by Boehringer Ingelheim (Germany), which was
dissolved in DMSO and stored at –20uC until use.
Full Viral Genomic Sequence Analysis
Viral RNA was extracted from primary virus culture superna-
tant by QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany).
Virus cDNA was synthesized from virus RNA using Super-
ScriptTM II Reverse Transcriptase (Invitrogen). Nearly 9.0 kb full
length genome of CNGZD was recovered by four independent
PCR reactions using 4 paired primers, in which the PCR products
at size of about 2.0–2.5 kb were overlapping the whole virus
genome except long terminal repeat (LTR) fragment. Each
segment of viral PCR products was subcloned into pMD18-T
Simple Vector (TaKaRa) using ligation kits (TaKaRa). Five
plasmids for each PCR segment were prepared for cycle
sequencing PCR. The sequence electrograms of each sample
were aligned using Staden Package [13] and all sequences were
assembled by Vector NTI advance 10 (Invitrogen). Virus coding
sequences (CDSs) were pointed out by online software HIV
Sequence Locator. Recombinant Identification Program (RIP) was
used for analysis of HIV-1 subtypes and recombinations. REGA
HIV-1 Subtyping Tool - Version 2.0 was used for confirmation of
virus subtypes [14]. Phylogenetic analysis was performed to figure
out the subtype of virus strain. Genotypic resistance interpretation
was also done using Stanford University HIV Drug Resistance
Database HIVdb program (version6.0.11) (http://hivdb.stanford.
edu). The viral genome sequence was annotated and deposited
into GenBank (accession number: JQ423923).
In Vitro Selection of CRF07_BC Variants Resistant to NVP
Primarily isolated virus strain and two biological clones of
CNGZD were used for in vitro selection of virus variants resistant to
NVP in three and two independent cultures, respectively,
according to the methods described previously [15]. Briefly,
PBMCs (16106) were initially infected with 26105 BFU/well of
the virus in a 24-well tissue culture plate (in quintuple) and
cultured in 1 ml medium containing diluted NVP. The starting
and ending NVP culture concentration was 5 nM and 64 mM,
respectively. One NVP untreated well was included as negative
control. At day 3, 7 and 10, virus titers in culture supernatant of
each well were detected by BFU assay. Once the BFU number in
NVP treated cultures was more than 20% of the untreated control,
the drug concentration was increased to 2-fold. While the BFU
number in NVP treated cultures was less than 5% of the untreated
control, restart the selection. The whole selection was carried out
for 25 passages. Passages were performed with supernatant of
preceding passage and conducted in the same rules mentioned
above. Culture supernatants of passage 5, 10, 15, 20 and 25 were
saved for genotypic and phenotypic resistance analysis.
Genetic Resistance Analysis in Resistant Variants
Viral RNA was extracted by QIAamp Viral RNA Mini kit
(Qiagen, Hilden, Germany) and viral cDNA was reverse-
transcribed using SuperScriptTM II Reverse Transcriptase (Invi-
trogen) according to the manufacturer’s protocol. The entire
protease gene and the first 440 codons of RT gene were amplified
from cDNA by high fidelity AccuPrimeTM Taq DNA Polymerase
(Invitrogen) using primers AV150 and polM4 as described
previously [16,17]. PCR products were purified using QIAquick
PCR Purification Kit (Qiagen) and analyzed on 1% TBE agarose
gel to confirm their size and purity. The purified PCR products
were direct sequenced in both directions using the Big Dye
terminator v3.1 cycle sequencing kit (Applied Biosystems). The
sequence results were aligned with Staden Package [13] and
submitted to the Stanford University HIV Drug Resistance
Database HIVdb program (version6.0.11)(http://hivdb.stanford.
edu) for the interpretation of genotypic resistance as described
previously [18].
Phenotypic Analysis of NVP Resistant Variants
Phenotypic analysis was performed in TZM-bl cells containing
luciferase reporter gene induced by HIV infection as described
previously [19]. Briefly, the TZM-bl cells were infected with 400–
600 BFUs/well of the virus and then added with 7 serial dilutions
of NVP in triplicate. After 48 hrs culture, luciferase activities were
tested by luciferase assay system (Promega) according to the
manufacturer’s protocol. The 50% effective concentration (EC50)
of NVP was determined according to the curve which was plotted
by the percentage of reduction of luciferase activity versus serial
NVP concentrations. NVP resistance of virus variant was
expressed as the fold change (FC) of NVP EC50. The NVP
susceptibility fold-change of virus variants was defined as the ratio
between the EC50 of drug resistant variants with certain mutations
and the EC50 of virus without the certain mutations.
Results
Analysis of the Viral Genome Sequence of CNGZD
Isolated from the Patient
The 9.0-kb full length viral genome of HIV strain CNGZD was
amplified to obtain the viral genome except the LTR at the 59
terminal. The sequence contained all the known viral genes,
including gag, pol, vif, vpr, tat, rev, vpu, env and nef coding for viral
proteins p17, p24, p2, p1, p6, PR, RT, IN, Vif, Vpr, Tat, Rev,
Vpu, gp120, gp41 and Nef, respectively (Table 1). The results of
subtyping analysis showed that CNGZD belonged to HIV-1
CRF07_BC as determined in both phylogenetic and bootscanning
methods using Rega HIV-1 subtyping tool (version 2.0) (Figure 1).
Mosaic structures from different subtypes in CNGZD were
confirmed by RIP and compared with that of CRF07_BC
reference strain 97CN54 (Figure 2). The sequence of CNGZD
was aligned with near-full-length consensus sequences of subtypes
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A1, A2, B, C, D, F1, F2, G, H, CRF01_AE in HIV database. The
distance value between the sequence of CNGZD and the subtype
marked by different color was calculated at each window size. The
subtype with the highest similarity to CRF07_BC in every moving
window was presented on the top of the graph. For CNGZD and
CRF07_BC reference strain 97CN54, five segments from subtype
B were found in subtype C backbone and the recombination
points located in similar positions at p17/p24, p7/p6, RT, Vpr/
Vpu, nef regions (Figure 2). The phylogenetic tree also showed
that CNGZD belonged to CRF07_BC clade together with other
clinical isolated virus (Figure 3). Pre-existing drug-resistant
mutations in PR and RT genes of CNGZD were analyzed by
Genotypic Resistance Interpretation Algorithm. No major or
minor PR mutations and no NRTI mutations were found in
CNGZD, but a NNRTI mutation V179E was detected, which was
predicted to cause low-level resistance to NVP, efavirenz (EFV)
and delavirdine (DLV) according to the comment of Stanford
University HIV drug resistance database [20]. Thus, CNGZD was
considered as a representative member of CRF07_BC and used
for the in vitro selection to investigate the NVP mutation profile in
clinical isolated CRF07_BC virus.
NVP-associated Mutations and Combination Profiles of
CRF07_BC Selected in vitro
CRF07_BC strain CNGZD was passaged with increasing
concentration of NVP to select the virus variants resistant to the
drug. No any mutation was detected in passage 5 of each parallel
culture. After 25 passages of PBMC cultures in the presence of
gradually increasing concentration of NVP, four combination
profiles of mutations, which were initialed by three previously
reported mutations A98G, V108I, Y181C [21,22], and reported
mutations I135T [23] together with a novel mutation I382L, were
identified (Figure 4). In these combination profiles, three
previously reported mutations K238N, V106M, V189I [24], and
6 novel mutations T48I, I178M, T386A, V314A, I382V and P4H
appeared gradually and formed combinations of up to 3–5
mutations at the end of the selection. Among them, I178M
appeared in four parallel cultures, while V106M was selected in
three independent virus cultures together with I178M. V108I was
also found in three selected mutants as initial or non-initial
mutation in our study. As summarized in Table 2, a total of seven
known mutations and seven novel mutations were identified in
NVP-selected variants. According to the comments given by
Stanford University HIV-1 Resistance Database, mutations
V106M and Y181C can cause high level resistance to NVP,
while mutations A98G and V108I just result in low-level reduction
in susceptibility to NVP. Another mutation K238N alone is not a
common mutation selected by NNRTI treatment and its effect on
resistance to NVP is still unknown [25]. Seven novel mutations
P4H, T48I, I178M, V314A, I382L/V and T386A have not been
reported to cause NVP resistance. All these mutations, including
the pre-existing congenital NNRTI minor mutation V179E,
persisted to the end of this in vitro study. These results showed
that NVP-selected mutations and their combination profile in
HIV-1 subtype CRF07_BC were complicate and diverse.
Phenotypic Analysis of CRF07_BC Virus Variants Selected
by NVP
To analyze the phenotypes of NVP-selected CRF07_BC virus
variants, the NVP susceptibility of 14 virus variants selected in the
in vitro culture was tested in TZM-bl cell cultures (Figure 5).
Among 4 variants with the initial mutations A98G, V108I,
Y181C, and I135T/I382L respectively, the variant with the
mutation Y181C showed the highest resistance to NVP, which
resulted in about 450 folds increase of NVP resistance. The EC50
of NVP in the variants with the mutations A98G or two other
mutations I135T/I382L increased for about 17 or 7 folds, while
that in the variant with mutation V108I increased for less than 4
folds. In one of the parallel culture, the initial mutation V108I
disappeared later in the subsequent selection cultures with higher
concentration of NVP. In the variants appeared subsequently in
the presence of increasing concentrations of NVP, the variant with
additional mutation V106M caused about 22–32 folds increase of
NVP resistance, while the variants with additional mutations
K238N/T48I/I178M and V108I/T386A showed about 5–10
folds increase of NVP resistance. The NVP resistance of the
variants with the other additional mutations V314A, V189I,
I178M and I178M/I382V increased for less than 4 folds, but the
mutation P4H was not related to NVP resistance. The drug
resistant effect of single mutation was further analyzed by
comparing NVP resistance in variants with different combinations
of mutations. For example, initial or subsequent mutation V108I
Table 1. Genomic regions covered by sequences of CNGZD.
CDS
Position
in HXB2
Amino acid
in HXB2 Position in CNGZD
NCR 654–789 7–52 1–136
Gag 790–2292 1–501 137–1624
p17 790–1185 1–132 137–523
p24 1186–1878 1–231 524–1216
p2 1879–1920 1–14 1217–1252
p7 1921–2085 1–55 1253–1417
p1 2086–2133 1–16 1418–1465
p6 2134–2292 1–53 1466–1624
Pol 2085–5096 1–1004 1417–4428
p2p7p1p6 1879–2292 1–138 1217–1624
GagPolTF 2085–2252 1–56 1417–1584
Protease 2253–2549 1–99 1585–1881
RT 2550–3869 1–440 1882–3201
RNase 3870–4229 1–120 3202–3561
Integrase 4230–5096 1–289 3562–4428
Vif 5041–5619 1–193 4373–4954
Vpr 5559–5850 1–98 4894–5184
Tat1 5831–6045 1–72 5165–5379
Rev1 5970–6045 1–26 5304–5379
Vpu 6062–6310 1–83 5396–5641
gp160 6225–8795 1–857 5559–8132
gp120 6225–7757 1–511 5559–7073
gp41 7758–8795 1–346 7074–8132
Tat2 8379–8469 1–31 7695–7785
Rev2 8379–8653 1–92 7695–7990
Nef 8797–9417 1–207 8133–8750
LTR3 9086–9673 1–184 8419–8992
All the coding sequences (CDSs) in CNGZD were pointed out and the
corresponding position of each CDS in the virus genome was indicated in both
submitted sequence and HIV-1 reference strain HXB2 by the online software
HIV Sequence Locator.
doi:10.1371/journal.pone.0044333.t001
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was associated with 3.5 or 3.1 folds increase of NVP resistance,
while mutations V108I/T386A accounted for 5 folds increase of
NVP resistance. Thus, NVP resistance of the variant with
mutation T386A alone should increase less than 4 folds as
compared to wild type. Similarly, the variants with additional
K238N/T48I/I178M, I178M/I382V and I135T/I382L resulted
in about 10, 3.5 and 7.3 folds increase of NVP resistance,
respectively. Therefore, the novel mutations I178M and I382L,
and the reported mutation I135T would be associated with low
level of NVP resistance (,4 folds increase).
Based on the results of NVP susceptibility, NVP-selected
mutations were classified to high (over 20-fold), medium (between
4 to 20-fold) and low (less than 4-fold) level resistance to NVP. As
summarized in Table 3, two reported mutations V106M and
Y181C were characterized to be associated with high level of NVP
resistance, while the other 5 known mutations A98G, K238N
V108I, I135T and V189I were classified as medium or low level of
NVP resistance. Among seven novel mutations, one (P4H) did not
show any NVP resistant effect and the other 6 were associated with
low level of NVP resistance. Even in the combination of two
mutations, I135T/I382I was associated with median level of NVP
resistance but I178M/I382V only gave rise to low level of NVP
resistance.
Drug resistant effects of the 5 reported mutations in CRF07_BC
virus were further compared with which were reported in Stanford
University HIV drug resistance database (Table 4). Mutations
V106M, V108I and Y181C in CRF07_BC were associated with
similar NVP resistance as that reported in the database, but A98G
in CRF07_BC might be related to higher NVP resistance than
that reported in the database. Furthermore, drug resistant effect of
K238N is reported to be unknown in the database, but it showed
low level of drug resistance in this study.
Discussion
Since there is no experimental and clinical data for NVP
resistant mutations of HIV CRF07_BC available yet, we designed
and performed an in vitro NVP selection study. Considering that
the results obtained from this study should be used for hypothetical
management of RTI treatments for HIV patients infected by this
CRF of the virus, we selected a clinical isolate of CRF07_BC virus
strain CNGZD, which was isolated from a HIV-1 infected patient,
to represent CRF07_BC. NVP was selected for this study, because
it has been included in the free ARV treatment in China and
currently used in AIDS patients.
The genome of CNGZD was sequenced to understand its
genetic background (Table 1, Figure 1, 2, and 3). CRF07_BC was
mainly from subtype C with 10 breakpoints and four portions of
subtype B’ in gag-pol region, vpr gene, 39 end of vpu gene and nef
gene. The subtype B’ segment in RT was at residues 144–243,
containing two of three highly conserved aspartate codons in
active sites of the enzyme. The residues 100–200 of RT plays the
role as polymerase catalytic site and serves as binding sites of
reverse transcriptase inhibitors (RTIs) [26]. The combination of
subtype B and C in RT, the key enzyme of HIV, may potentially
result in different genotypic and phenotypic drug resistance in
CRF_BC virus. It inspired us to explore the drug resistant
mutations in RT of this unique CRF.
Figure 1. Subtyping analysis of the genome of CNGZD using Rega HIV-1 subtyping tool (version 2.0). The recombination pattern was
determined by comparing CNGZD sequence with reference sequences of HIV-1 pure subtypes A, B, C, D, F, G, H, J, K. Five DNA segments from
subtype B were found to be integrated into the genomic backbone of subtype C by phylogenetic methods of the Rega HIV-1 subtyping tool, which
can identify the subtype of a specific sequence. The result was displayed as a virus genomic structure figure with subtype components (A). For
subtype recombination analysis, reference sequences of different pure subtypes and CRFs were further applied for the comparison of the virtually
full-length sequence of CNGZD by bootscanning methods. Bootscan analysis showed that CNGZD belonged to CRF07_BC (B).
doi:10.1371/journal.pone.0044333.g001
Figure 2. Analysis of nearly full length genome of CNGZD using Recombinant Identification Program (RIP) (version 3.0). Mosaic
structures of subtype B (in blue) and C (in violet) in both CNGZD and the reference strain of CRF07_BC (97CN54) were figured out by software RIP and
the recombinant profile of CNGZD was similar to the reference strain 97CN54. Five segments from subtype B were found in subtype C backbone and
the recombination points located at positions in p17/p24, p7/p6, RT, Vpr/Vpu and nef regions of CNGZD and 97CN54, respectively. Window size: 200;
threshold for statistical significance: 90%.
doi:10.1371/journal.pone.0044333.g002
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Figure 3. Phylogenetic analysis of clinical isolated virus strain CNGZD. A neighbor joining phylogenetic tree was built by Mega 4.1 based on
full length sequences of clinical isolated virus strain CNGZD and different pure subtypes and CRFs. The Kimura 2-parameter substitution model was
used and bootstrap values (1000 replicates) higher than 50 were shown next to the nodes of the tree. J.SE. SE9280 with long distance to CRF07_BC
was selected as an outgroup in the phylogentic tree. Subtype references were downloaded from the Los Alamos HIV database (http://hiv-web.lanl.
gov). CNGZD located in a clade with the other CRF07_BC isolates. Bar: 0.002 substitutions per site.
doi:10.1371/journal.pone.0044333.g003
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Primarily isolated virus strain and biological clones of CNGZD
were cultured in PBMCs with increasing concentration of NVP.
We cannot exclude the possibility of selecting pre-existing minority
drug resistant variants from the quasi-species which were not
revealed by the Sanger-based population sequencing. However, it
has been reported that the pre-existing virus variants will emerge
soon after 1 or 2 passages by in vitro selection [27]. In our study,
NVP-related virus variants were selected after passage 5 and virus
strain CNGZD was isolated from an ART treatment naive patient.
Thus, the probability of selecting pre-existing minority NVP-
resistant variants is quite low. The selection experiment was
terminated at 25 passages with 64 mM of NVP because 1) the virus
titer of resistant variants in passage 20 to 25, which cultured with
64 mM NVP, was less than 10–20% of the untreated control, so
that it was hard to scale up the drug concentration after a few
passages of culture with the same NVP concentration; 2) the
64 mM NVP was also reported as the end point of the other in vitro
selection study [28]. Genotyping and phenotyping of virus variants
were performed in different passages of five parallel cultures,
respectively. Population sequencing was adopted for genotyping
and it has been reported that this Sanger-based sequencing is able
to reveal the majority viruses up to 80–90% of the whole
population [29]. The mutation profiles and their resistance effects
could be correlated because genotypes and phenotypes of virus
variants in serial passages of each parallel culture were consecutive
and consistent.
NVP resistance mutations are complicate and variable. Thus
far, about 32 NVP-resistance associated mutations in 17 positions,
including 15 major NVP-resistant mutations at 5 positions
(K103NST, V106AM, Y181CIV, Y188LHC, G190ASEQ), have
been summarized in HIV drug resistance database of Stanford
University [30,31]. Y181C, K103N, G190A, H221Y, K101E,
A98G, V108I, V106A, E138A, Y188L are the top ten most
common mutations resistant to NVP in patients who received
NVP treatment [32]. Two mutations, V106M and Y181C, have
been reported to be major drug resistant mutations [32].
According to Mutation ARV Evidence Listing (MARVEL),
V106M appeared in 14% NNRTI treated patients with subtype
C HIV infection, whereas it was found in only 0.5% of the treated
patients carrying subtype B virus [33]. It seemed that V106M were
inclined to develop in subtype C virus. Interestingly, V106M
development bias was only found under EFV but not NVP
treatment in the previous studies and there was no significant
difference of V106M prevalence between subtype B and C in
patients receiving NVP treatment [34,35]. In this study, V106M
developed in three out of five parallel cultures. This may be due to
those residues 143–200 of RT in CRF07_BC are from subtype B,
while the other part of RT, including amino acid 106, are from
subtype C. CRF07_BC may inherit V106M development
Figure 4. Combination profiles of mutations selected by NVP in CRF07_BC. Mutations that were bolded are novel mutations. Four different
combination profiles initialed with mutations A98G, V108I, Y181C and I135T with I382L were selected by NVP in CRF07_BC.
doi:10.1371/journal.pone.0044333.g004
Table 2. Mutations developed in RT gene of CRF07_BC strain CNGZD during the in vitro selection with increasing concentrations
of NVP.
NVP associated mutations predicted by HIVdb program
98 106 108 135 181 189 238
B, C, CRF07_BC cons A V V I Y V K
NVP G M I T C I N
Novel mutations
4 48 178 314 382 386
B, C, CRF07_BC cons P S,T I V I T
NVP H I M A L/V A
The conserved amino acid at position 48 of subtype B is S while that in subtype C and CNGZD is T.
doi:10.1371/journal.pone.0044333.t002
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preference from subtype C by NNRTI treatment. As shown in
MARVEL, the prevalence of the other major mutation Y181C in
NNRTI treated patients with subtype B and C virus are 21% and
12%, respectively. This indicated that both subtype B and C
viruses were likely to develop Y181C after receiving NNRTI
treatment. In the present study, Y181C was developed in one of
five parallel cultures, suggesting that this major drug resistant
mutation would also appear in patients infected with CRF07_BC
virus after receiving NVP therapy.
The other two mutations, A98G and V108I, have been reported
to be polymorphic accessory mutations in patients with subtype B
or C virus, while K238N is rarely selected by NNRTI and not
common to be found in NNRTI-treated patients with infection of
subtype B or C virus (prevalence,0.5%) [33]. Furthermore, seven
novel mutations in 6 positions of RT were selected in this study.
Polymorphisms at position 4, 48, 135, 178 of RT have been
reported in CRF07_BC in China but only I135T was found in
treatment naı¨ve patients with CRF07_BC infection [5,36]. It has
been reported that the polymorphic rate in the first 255 codons of
RT in CRF07_BC was nearly 3 fold higher than that in subtype B
[36]. Consistently, all 7 reported mutations and 3 of 7 novel
mutations selected in this study appeared in positions within the
first 255 codons of RT. Since the residues 144–243 in RT of
CRF07_BC were from subtype B and the residues 100–200 of RT
serves as binding sites of RTIs [26], highly frequent genetic
variations of CRF07_BC in this region of RT may be associated
with rapid and/or novel development of drug resistance in this
recombinant virus.
NVP selected variants were defined to 4 combination profiles
based on the initial mutations appearing in the selection period.
Initial mutations A98G, V108I and Y181C appeared during the
first 10 passages in the presence of 800 nM NVP (4-fold of
EC50), while double mutations I135T/I382L were detected
between passages 10 and 15 (Figure 4). In previous in vitro studies,
both Y181C and V106A have been reported as initial mutations
resistant to NVP in both subtype B and C viruses [22,27,28,35],
but V106A was not an initial mutation selected by NVP treatment
in this study. Similarly, V108I has been found in both subtype B
and C viruses, whereas A98S was only detected in subtype C virus
[35]. The low mutation barrier at these positions suggests that
A98G, V108I and Y181C may be found in NVP treated patients
infected with CRF07_BC with high possibility. Furthermore, some
mutations are likely to appear after the emergence of certain
mutations. For example, V108I has been reported to correlate
with the appearance of Y181C in the patients or in cell culture as
an accessory mutation [32,35] and it also recurred in the present
study. Our results also showed that V106M was likely to
accumulate with I178M in CRF07_BC. The complex NNRTI
Figure 5. Phenotypic analysis of CRF07_BC virus variants selected by NVP. The NVP EC50 of CRF07_BC virus variants with different
mutations were shown. TZM-bl cells were infected with virus variants and treaded with serial diluted NVP. After 48 hrs incubation, luciferase activities
representing HIV infection were tested. The EC50 NVP was estimated from the standard curve plotted by the percentage of reduction of luciferase
activity and serial concentrations of NVP.
doi:10.1371/journal.pone.0044333.g005
Table 3. Characterization of NVP resistance mutations in
CRF07_BC virus.
Increased folds of EC50
.20 4–20 ,4
V106M A98G* (V108I)*
Y181C* (V108I)/T386A I135T
I135T/I382L* (I178M)
K238N/T48I/(I178M) V189I
V314A
I382L
T386A
(I178M)/I382V
Novel mutations were bold. Initial mutations were labeled with *. Mutations in
parentheses appeared in different mutation profiles.
doi:10.1371/journal.pone.0044333.t003
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mutations developed in CRF07_BC in vitro selection may be highly
possible to occur in clinics.
In summary, this study has showcased the evolution of virus
resistance to NVP in clinical isolated CRF_07BC virus by in vitro
PBMC culture system. Our study identified 7 novel mutations and
7 reported mutations selected by NVP treatment that are
associated with different levels of drug resistance to NVP. The
results have also suggested that major NNRTI mutations Y181C
and V106M may be found in patients harboring CRF07_BC virus
with high possibility when NVP was included in ART treatment
and these two mutations may cause serious resistance to not only
NVP but also other NNRTI. Furthermore, novel mutations have
been selected by NVP treatment in diverse and variable
combination with the other major mutations in our study. This
phenomenon may happen when more and more patients infected
with different HIV CRFs come into therapy. Although the
information obtained in this in vitro selection study will not fully
cover the resistant mutations which will actually occur in patients,
it has still provided useful information for rational management of
ART in patients infected with HIV CRF_07BC subtype.
Acknowledgments
We are highly appreciative of the resources made available by the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH; these include TZM-bl from Drs. John C. Kappes, Xiaoyun Wu and
Tranzyme Inc.
Author Contributions
Conceived and designed the experiments: BJZ. Performed the experiments:
HW HJZ XMZ. Analyzed the data: HW BJZ. Contributed reagents/
materials/analysis tools: HFX MW HW HJZ BJZ. Wrote the paper: HW
JDH BJZ.
References
1. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, et al. (2000) HIV-1
nomenclature proposal. Science 288: 55–56.
2. Hemelaar J, Gouws E, Ghys PD, Osmanov S, Isolation W-UNfH, et al. (2011)
Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 25:
679–689.
3. Su L, Graf M, Zhang Y, von Briesen H, Xing H, et al. (2000) Characterization
of a virtually full-length human immunodeficiency virus type 1 genome of a
prevalent intersubtype (C/B’) recombinant strain in China. J Virol 74: 11367–
11376.
4. Tee KK, Pybus OG, Li XJ, Han X, Shang H, et al. (2008) Temporal and spatial
dynamics of human immunodeficiency virus type 1 circulating recombinant
forms 08_BC and 07_BC in Asia. J Virol 82: 9206–9215.
5. Yu G, Li Y, Li J, Diao L, Yan X, et al. (2009) Genetic diversity and drug
resistance of HIV type 1 circulating recombinant Form_BC among drug users in
Guangdong Province. AIDS Res Hum Retroviruses 25: 869–875.
6. Ye JR, Yu SQ, Lu HY, Wang WS, Xin RL, et al. (2011) Genetic Diversity of
HIV Type 1 Isolated from Newly Diagnosed Subjects (2006–2007) in Beijing,
China. AIDS Res Hum Retroviruses.
7. Li T, Dai Y, Kuang J, Jiang J, Han Y, et al. (2008) Three generic nevirapine-
based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric
observation cohort. PLoS One 3: e3918.
8. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: an updated
framework for the second decade of HAART. AIDS Rev 10: 67–84.
9. Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA (2008) Role of genetic
diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review
of virologic and biochemical evidence. AIDS Rev 10: 212–223.
10. van ‘t Wout AB, Schuitemaker H, Kootstra NA (2008) Isolation and propagation
of HIV-1 on peripheral blood mononuclear cells. Nat Protoc 3: 363–370.
11. Zhang Q, Zhang X, Wu H, Seto D, Zhang HJ, et al. (2012) Parental LTRs Are
Important in a Construct of a Stable and Efficient Replication-Competent
Infectious Molecular Clone of HIV-1 CRF08_BC. PLoS One 7: e31233.
12. Zhang HJ, Wang YX, Wu H, Jin DY, Wen YM, et al. (2009) The y271 and i274
amino acids in reverse transcriptase of human immunodeficiency virus-1 are
critical to protein stability. PLoS One 4: e6108.
13. Staden R, Beal KF, Bonfield JK (2000) The Staden package, 1998. Methods
Mol Biol 132: 115–130.
14. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An
automated genotyping system for analysis of HIV-1 and other microbial
sequences. Bioinformatics 21: 3797–3800.
15. Michael N, Kim JH (1999) HIV protocols. Totowa, N.J. Humana Press.
16. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, et al. (2000)
Genetic diversity of protease and reverse transcriptase sequences in non-subtype-
B human immunodeficiency virus type 1 strains: evidence of many minor drug
resistance mutations in treatment-naive patients. J Clin Microbiol 38: 3919–
3925.
17. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, et al. (2006) Natural
polymorphism in protease and reverse transcriptase genes and in vitro
antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive
patients. J Clin Virol 36: 43–49.
18. Chen JH, Wong KH, Chan K, Lam HY, Lee SS, et al. (2007) Evaluation of an
in-house genotyping resistance test for HIV-1 drug resistance interpretation and
genotyping. J Clin Virol 39: 125–131.
19. Takeuchi Y, McClure MO, Pizzato M (2008) Identification of gammaretro-
viruses constitutively released from cell lines used for human immunodeficiency
virus research. J Virol 82: 12585–12588.
20. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, et al. (2010)
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor
(NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob
Agents Chemother 54: 718–727.
21. Byrnes VW, Emini EA, Schleif WA, Condra JH, Schneider CL, et al. (1994)
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral
variants expressing multiple resistance-engendering amino acid substitutions to
reserve transcriptase inhibitors. Antimicrob Agents Chemother 38: 1404–1407.
22. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, et al. (1991) Human
immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of
reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 88: 11241–
11245.
23. Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, et al. (2007)
Characterization and structural analysis of novel mutations in human
Table 4. Comparison of drug-resistant effects between reported mutations selected in this study and those in HIV drug resistance
database of Stanford University.
Drug Mutations Level of resistance (increased folds of EC50)
In this study In HIV drug resistance database of Stanford University
NVP A98G M (17) L (2–3)
V106M H (22–32) H (70)
V108I L (3) L (UD)
Y181C H (450) H (123)
K238N L Unknown
H: high level of resistance (Fold change (FC).20); M: medium level of resistance (20.FC.4); L: low level of resistance (FC,4). UD: undetected. They were defined
according to Stanford database http://hivdb.stanford.edu/cgi-bin/Marvel.cgi.
doi:10.1371/journal.pone.0044333.t004
Identification of NVP Mutations in CRF07_BC
PLOS ONE | www.plosone.org 9 September 2012 | Volume 7 | Issue 9 | e44333
immunodeficiency virus type 1 reverse transcriptase involved in the regulation of
resistance to nonnucleoside inhibitors. J Virol 81: 11507–11519.
24. Kleim JP, Rosner M, Winkler I, Paessens A, Kirsch R, et al. (1996) Selective
pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency
virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in
the emergence of nucleoside RT-inhibitor-specific (RT Leu-74–.Val or Ile and
Val-75–.Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A 93: 34–38.
25. Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, et al. (2009)
Compilation and prevalence of mutations associated with resistance to non-
nucleoside reverse transcriptase inhibitors. Antivir Ther 14: 103–109.
26. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, et al. (2004)
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus
production without evolution in treated adults with undetectable HIV loads.
J Infect Dis 189: 1452–1465.
27. Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR, et al. (1992)
In vitro selection and molecular characterization of human immunodeficiency
virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol
Pharmacol 41: 446–451.
28. Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, Lopez-Galindez C (2002) In
vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine
and fitness determination of resistant variants. J Gen Virol 83: 93–101.
29. Services DoHaH (2011) Guidelines for the use of antiretroviral agents in HIV-1-
infected adults and adolescents. Panel on Antiretroviral Guidelines for Adults
and Adolescents: 174.
30. Conway B, Wainberg MA, Hall D, Harris M, Reiss P, et al. (2001) Development
of drug resistance in patients receiving combinations of zidovudine, didanosine
and nevirapine. AIDS 15: 1269–1274.
31. Casado JL, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, et al. (2000)
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing
a nevirapine plus protease inhibitor-containing regimen. AIDS 14: F1–7.
32. Reuman EC, Rhee SY, Holmes SP, Shafer RW (2010) Constrained patterns of
covariation and clustering of HIV-1 non-nucleoside reverse transcriptase
inhibitor resistance mutations. J Antimicrob Chemother 65: 1477–1485.
33. Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, et al. (2006) HIV-
1 pol mutation frequency by subtype and treatment experience: extension of the
HIVseq program to seven non-B subtypes. AIDS 20: 643–651.
34. Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, et al. (2004)
Genetic variation at NNRTI resistance-associated positions in patients infected
with HIV-1 subtype C. AIDS 18: 909–915.
35. Loemba H, Brenner B, Parniak MA, Ma’ayan S, Spira B, et al. (2002) Genetic
divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse
transcriptase (RT) and rapid development of resistance against nonnucleoside
inhibitors of RT. Antimicrob Agents Chemother 46: 2087–2094.
36. Liao L, Xing H, Li X, Ruan Y, Zhang Y, et al. (2007) Genotypic analysis of the
protease and reverse transcriptase of HIV type 1 isolates from recently infected
injecting drug users in western China. AIDS Res Hum Retroviruses 23: 1062–
1065.
Identification of NVP Mutations in CRF07_BC
PLOS ONE | www.plosone.org 10 September 2012 | Volume 7 | Issue 9 | e44333
